Emerge Nutraceuticals a Wholly Owned Subsidiary of Metwood Inc., Signs MOU to Acquire Cholesterade
By:
Metwood, Inc. via
AccessWire
July 18, 2022 at 11:00 AM EDT
MOUNT DORA, FL / ACCESSWIRE / July 18, 2022 / Today, Metwood (OTC PINK:MTWD), Emerge Nutraceuticals, has announced that they have entered into a MOU to acquire Cholesterade®, from Go Epic Health, Inc., a wholly owned subsidiary of LEON ( LEON ) for an undisclosed number of shares and is expected to close sometime within the 3 rd quarter. Cholesterade ® is a natural, acai-fiber-based powder supplement containing 7 grams of fiber per serving and easily soluble in water. It comes in three flavors: Mixed Berry, Orange and Lemon Lime. Clinically proven to reduce cholesterol over 8 weeks. The creator of this revolutionary product is none other than Dr. J. Robert Cade. Dr. J. Robert Cade was an American physician, university professor, research scientist and inventor. He is most widely remembered as the leader of the research team that formulated the sports drink Gatorade®. www.Cholesterade.com Emerge Nutraceuticals (MTWD) is a nutraceutical manufacturer selling proprietary soft gels, powders, and liquid formulations for vitamins, proteins and the body-building industry. The company has their own branded products in addition to wholesale white label manufacturing. The mission is to deliver organic, healthy solutions and natural alternatives to individuals seeking non-prescription remedies to better their health. www.emergenutraceuticals.com About Emerge Nutraceuticals Emerge Nutraceuticals is a nutraceutical manufacturer selling proprietary soft gels, powders, and liquid formulations for vitamins, proteins and the body-building industry. The company has their own branded products in addition to wholesale and white label manufacturing. About Cholesterade Cholesterade® was created by the late Dr. Robert Cade, the creator of Gatorade®. Cholesterade provides a natural, delicious and economical solution to help meet NIH requirements for therapeutic lifestyles changes using non-drug intervention to lower cholesterol prior to consideration of statin intervention. Forward-Looking Statements Disclosure: This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions. Contact: Keith Thomas, CEO James Price SOURCE: Metwood, Inc. View source version on accesswire.com: https://www.accesswire.com/708908/Emerge-Nutraceuticals-a-Wholly-Owned-Subsidiary-of-Metwood-Inc-Signs-MOU-to-Acquire-Cholesterade More NewsView More
Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead ↗
Today 10:22 EST
Via MarketBeat
Microsoft’s AI Superfactory Could Power a Stock Rally ↗
Today 9:27 EST
3 Big Tech Stocks Sliding: What’s Behind the Drop? ↗
Today 8:11 EST
Wall Street Sees a Winner in Take-Two Stock. Should You? ↗
Today 7:29 EST
Via MarketBeat
Tickers
TTWO
Datavault AI Just Raised Guidance by 400%—Are You Paying Attention? ↗
November 20, 2025
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|